A Randomized Phase 2 Study of DACOGEN (Decitabine) Plus JNJ-56022473 (Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML who are not Candidates for Intensive Chemotherapy
A study for patients with Acute Myeloid Leukemia (AML) using study drug decitabine
Sponsor: Janssen Research & Development, LLC
Enrolling: Male and Female Patients
IRB Number: AAAQ6852
U.S. Govt. ID: NCT02472145
Contact: Richard Carvajal MD: 212-304-5485 / rdc2150@cumc.columbia.edu
Additional Study Information: This study is for patients with Acute Myeloid Leukemia (AML). The purpose of this study is to determine if decitabine plus JNJ-56022473 can be safely combined and is active for your disease. The study drugs used in this study are JNJ-56022473, an experimental drug and DACOGEN ( also known generic as decitabine), a drug already used to treat your type of disease.
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Have you been diagnosed with Acute Myeloid Leukemia (AML)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Richard Carvajal MD
rdc2150@cumc.columbia.edu
212-304-5485
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE